Gilead Sciences' Kite Pharma has mapped out another route to the development of allogeneic or 'off-the-shelf' cell therapies for cancer, using technology developed by Appia Bio, a US startup ...

Shares of biotech Galapagos NV (GLPG) dipped nearly 1% in pre-market trade on Tuesday after the company announced the ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Galapagos (GLPG) announced the departure of its CFO and COO, Thad Huston, effective as of August 1. Huston has decided to leave the company and ...

Through its partnership in 2017 with California-based Kite Pharma, Fosun Pharma has been co-developing the CAR-T therapy in China. Its biopharmaceutical platform, Henlius is developing biosimilars ...

In the latest episode of The Centrifuge Sessions, hear from Samuel Haile, Ph.D., Director of Cell Biology at Kite Pharma, on how we're working to deliver cell therapies that offer new hope for ...